13 completed, 9 recruiting, 7 active not recruiting, 7 unknown. 29 Phase 2, 12 Phase 3, 2 Phase 1, 1 Phase 4.
Follow Gruppo Oncologico del Nord-Ovest: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 4 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 280 | 2026-09-15 | 2026-07-24 |
| Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), CAPOX (oxaliplatin/capecitabine), CDDP, 5 Fu - Gastroesophageal Adenocarcinoma | Phase 3 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 244 | 2026-09-01 | 2026-08-18 |
| Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic., placebo capsule, Pembolizumab - Head & Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 45 | 2026-01-27 | 2026-03-20 |
| Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. Trastuzumab-Deruxtecan (T-DXd), Capecitabine, Bevacizumab - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 42 | 2025-10-20 | 2026-02-17 |
| Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. Oxaliplatin, Irinotecan (CPT-11), Leucovorin - Pancreatic Adenocarcinoma Advanced or Metastatic | Phase 3 | Recruiting | Gruppo Oncologico del Nord-Ovest | 340 | 2025-03-27 | 2026-09-09 |
| Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. Cetuximab/avelumab - Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 67 | 2025-02-20 | 2025-03-14 |
| FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. Atezolizumab, Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 3 | Recruiting | Gruppo Oncologico del Nord-Ovest | 238 | 2024-11-15 | 2025-12-08 |
| Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC Cetuximab, Encorafenib - Colorectal Cancer | Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 16 | 2024-07-23 | 2026-09-09 |
| Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients 166Holmium TARE, Cetuximab, Panitumumab - Colorectal Cancer Metastatic | Phase 2 | Terminated | Gruppo Oncologico del Nord-Ovest | 4 | 2024-03-13 | 2026-01-05 |
| Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease Experimental, Control - Gastric Cancer, HER2-positive Gastric Cancer | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 46 | 2024-03-01 | 2026-09-23 |
| CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence Gemcitabine, Nab paclitaxel, Cisplatin - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Recruiting | Gruppo Oncologico del Nord-Ovest | 300 | 2023-11-07 | 2026-09-09 |
| Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule - Stage II Colon Cancer, Stage III Colon Cancer | Phase 2 | Suspended | Gruppo Oncologico del Nord-Ovest | 477 | 2023-05-17 | 2026-02-03 |
| Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) Trastuzumab deruxtecan, Durvalumab, Panitumumab - Colorectal Cancer, Resectable Colorectal Carcinoma | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 197 | 2023-05-11 | 2026-09-11 |
| Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery Retifanlimab, Cisplatin, Etoposide - Merkel Cell Carcinoma | Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 36 | 2022-12-07 | 2026-01-14 |
| Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer Pembrolizumab - Nasopharyngeal Carcinoma | Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 30 | 2022-03-24 | 2026-06-01 |
| Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. Capecitabine, Bevacizumab, Trifluridine/Tipiracil - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 48 | 2022-01-25 | 2026-05-20 |
| Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 Irinotecan, Oxaliplatin, Lederfolin - Locally Advanced Rectal Cancer | Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 63 | 2022-01-25 | 2026-07-24 |
| TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. Durvalumab, Tremelimumab - Gastric Cancer, Microsatellite Instability | Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 31 | 2021-04-01 | 2026-09-11 |
| Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC Niraparib - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 49 | 2021-02-08 | 2022-08-04 |
| Tailored Sonidegib Schedule After Complete Response in BCC Sonidegib - Locally Advanced Basal Cell Carcinoma | Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 21 | 2021-01-12 | 2026-06-01 |
Showing 20 of 41. Sign in to see all of them.
Colorectal Neoplasms (16) · Colonic Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (5) · Neoplasm Metastasis (3) · Rectal Neoplasms (3) · Head and Neck Neoplasms (2) · Nasopharyngeal Carcinoma (2) · Stomach Neoplasms (2) · Anus Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Squamous Cell (1) · Cholangiocarcinoma (1) · Liver Neoplasms (1) · Microsatellite Instability (1)
Fluorouracil (17) · Irinotecan (15) · Leucovorin (15) · Oxaliplatin (14) · Bevacizumab (10) · Capecitabine (8) · Cetuximab (8) · Panitumumab (6) · avelumab (5) · Cisplatin (4) · Drug Therapy (2) · Gemcitabine (2) · Nivolumab (2) · Radiotherapy (2) · atezolizumab (2)
Italy (39) · Germany (2) · Spain (2) · France (1)
Alfredo Falcone, MD (7) · Filippo Pietrantonio, MD (5) · Chiara Cremolini, MD, PhD (3) · Carlotta Antoniotti, MD, PhD (2) · Monica Niger, MD (2) · Paolo Bossi (2) · Roberto Moretto, MD (2) · Alfredo Falcone, MD, PhD (1) · Emilio Bajetta, MD (1) · Federica Morano, MD (1) · Gianluca Masi, MD (1) · Lisa Licitra, prof (1) · Paolo Bossi, Dr. (1)
PMID 26861604, PMID 27986363, PMID 32816630, PMID 35594613, PMID 36822922, PMID 12927569, PMID 16476835, PMID 20702138, PMID 24728035, PMID 25337750, PMID 25600568, PMID 25712456, PMID 26338525, PMID 28599628, PMID 29370781, PMID 29450468, PMID 29487697, PMID 29873679, PMID 30018814, PMID 30293873, PMID 30476968, PMID 30914290, PMID 30998813, PMID 32164906, PMID 32698790, PMID 34815354, PMID 35366570, PMID 35636444, PMID 35666229, PMID 36753836, PMID 36880426, PMID 37368098, PMID 37535876, PMID 38589856, PMID 38592721, PMID 38865678, PMID 39637944, PMID 40200187, PMID 40340830, PMID 41115464, PMID 41252656, PMID 41318310, PMID 41505697
2017 (4), 2009 (1), 2015 (1), 2018 (1), 2019 (1), 2023 (1), 2025 (1)